Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies Ltd has successfully raised $30 million through a targeted share placement at $16.00 per share to fund its ongoing medical device developments and preparatory activities for regulatory approval studies. The funds are earmarked for the advancement of their prime product, DurAVR® THV, in-house manufacturing scale-up, and other R&D efforts. With this new capital, Anteris is poised to further its FDA approval process and market pre-launch activities for the innovative heart valve technology.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
